Insider Selling: Centessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Sells 11,742 Shares of Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) insider Gregory M. Weinhoff sold 11,742 shares of the stock in a transaction dated Friday, October 25th. The shares were sold at an average price of $15.38, for a total value of $180,591.96. Following the transaction, the insider now directly owns 183,266 shares in the company, valued at approximately $2,818,631.08. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Centessa Pharmaceuticals Price Performance

CNTA stock remained flat at $15.50 on Friday. 170,175 shares of the company were exchanged, compared to its average volume of 395,545. The stock has a market capitalization of $1.56 billion, a price-to-earnings ratio of -10.92 and a beta of 1.46. Centessa Pharmaceuticals plc has a fifty-two week low of $5.58 and a fifty-two week high of $17.59. The company has a 50 day simple moving average of $14.98 and a two-hundred day simple moving average of $11.48. The company has a quick ratio of 13.29, a current ratio of 13.29 and a debt-to-equity ratio of 0.27.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.02). As a group, research analysts expect that Centessa Pharmaceuticals plc will post -1.68 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the company. Jefferies Financial Group increased their price target on Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a "buy" rating in a report on Wednesday, September 11th. BMO Capital Markets upped their price objective on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the stock an "outperform" rating in a report on Monday, September 16th. Morgan Stanley upgraded shares of Centessa Pharmaceuticals from an "equal weight" rating to an "overweight" rating and lifted their target price for the stock from $11.00 to $26.00 in a report on Thursday, September 19th. B. Riley assumed coverage on shares of Centessa Pharmaceuticals in a report on Thursday, September 19th. They set a "buy" rating and a $33.00 price target for the company. Finally, Oppenheimer reaffirmed an "outperform" rating and issued a $14.00 price target on shares of Centessa Pharmaceuticals in a research report on Wednesday, August 14th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $25.17.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. boosted its stake in Centessa Pharmaceuticals by 99.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 13,593 shares of the company's stock worth $217,000 after buying an additional 6,785 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Centessa Pharmaceuticals by 47.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company's stock valued at $40,000 after acquiring an additional 826 shares in the last quarter. Harbour Capital Advisors LLC bought a new stake in Centessa Pharmaceuticals in the third quarter valued at about $259,000. GAMMA Investing LLC raised its position in Centessa Pharmaceuticals by 103.1% in the third quarter. GAMMA Investing LLC now owns 2,972 shares of the company's stock worth $48,000 after purchasing an additional 1,509 shares in the last quarter. Finally, Nantahala Capital Management LLC acquired a new stake in Centessa Pharmaceuticals during the second quarter valued at approximately $4,064,000. Institutional investors and hedge funds own 82.01% of the company's stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.